Chinese Alzheimer’s Drug Gets U.S. Approval for Stateside Trial

Published April 26, 2020

A Chinese drugmaker has received approval from Food and Drug Administration (FDA) to start clinical trials in the U.S. for a breakthrough Alzheimer’s drug as it seeks global validation for the controversial therapy.

Related Stories